Category: 110256-15-0

Application of 110256-15-0, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 110256-15-0, Name is 5-Cyclopropylisoxazole-3-carboxylic acid,introducing its new discovery.

SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 110256-15-0, and how the biochemistry of the body works.Application of 110256-15-0

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

110256-15-0, Name is 5-Cyclopropylisoxazole-3-carboxylic acid, belongs to Isoxazoles compound, is a common compound. HPLC of Formula: C7H7NO3In an article, once mentioned the new application about 110256-15-0.

ISOXAZOLE CARBOXAMIDES AS IRREVERSIBLE SMYD INHIBITORS

The present disclosure provides provides substituted isoxazole carboxamides having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, X, n, and m are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 110256-15-0

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

110256-15-0, Name is 5-Cyclopropylisoxazole-3-carboxylic acid, belongs to Isoxazoles compound, is a common compound. SDS of cas: 110256-15-0In an article, once mentioned the new application about 110256-15-0.

A new class of bradykinin B1 receptor antagonists with high oral bioavailability and minimal PXR activity

The design and synthesis of a novel class of human bradykinin B1 antagonists featuring difluoroethyl ether and isoxazole carboxamide moieties are disclosed. Compound 7g displayed excellent pharmacokinetic properties, efficient ex vivo receptor occupancy, and low potential for P450 induction via PXR activation.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 110256-15-0

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Related Products of 110256-15-0, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 110256-15-0, Name is 5-Cyclopropylisoxazole-3-carboxylic acid,introducing its new discovery.

SUBSTITUTED PIPERIDINE COMPOUNDS

The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 110256-15-0, and how the biochemistry of the body works.Related Products of 110256-15-0

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

In heterogeneous catalysis, the catalyst is in a different phase from the reactants. category: Isoxazoles, At least one of the reactants interacts with the solid surface in a physical process called adsorption in such a way. 110256-15-0, name is 5-Cyclopropylisoxazole-3-carboxylic acid. In an article£¬Which mentioned a new discovery about 110256-15-0

Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors

We report herein the discovery of isoxazole amides as potent and selective SET and MYND Domain-Containing Protein 3 (SMYD3) inhibitors. Elucidation of the structure-activity relationship of the high-throughput screening (HTS) lead compound 1 provided potent and selective SMYD3 inhibitors. The SAR optimization, cocrystal structures of small molecules with SMYD3, and mode of inhibition (MOI) characterization of compounds are described. The synthesis and biological and pharmacokinetic profiles of compounds are also presented.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 110256-15-0, help many people in the next few years.category: Isoxazoles

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 14. Preparation of N-(1-benzyl-1H-pyrazol-4-yl)-5-cyclopropylisoxazole-3-carboxamide (119) To a solution of 1-benzyl-1H-pyrazol-4-amine (0.050 g, 0.289 mmol), 5-cyclopropylisoxazole-3-carboxylic acid (44.1 mg, 0.289 mmol) and 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (109 mg, 0.289 mmol) in N,N’-dimethylformamide (1 mL) at 25 C. was added diisopropylethylamine (0.075 mL, 0.433 mmol). The reaction mixture was stirred at 25 C. for 16 h. The reaction mixture was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL*3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude residue was purified by column chromatography (ISCO, 12 g silica, eluting with 40% ethyl acetate/hexanes for 20 min) to give N-(1-benzyl-1H-pyrazol-4-yl)-5-cyclopropylisoxazole-3-carboxamide (12.4 mg, 0.041 mmol, 14%) as an off-white solid. 1H NMR (300 MHz, Chloroform-d) delta 8.42 (s, 1H), 8.00 (s, 1H), 7.59 (s, 1H), 7.37-7.18 (m, 5H), 6.39 (s, 1H), 5.30 (s, 2H), 2.11 (tt, J=8.5, 5.0 Hz, 1H), 1.23-1.08 (m, 2H), 1.08-0.92 (m, 2H); LCMS (ESI) m/z: 309.2 [M+H]+.

110256-15-0, 110256-15-0 5-Cyclopropylisoxazole-3-carboxylic acid 1092113, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; Yumanity Therapeutics, Inc.; WRONA, Iwona; TIVITMAHAISOON, Parcharee; TARDIFF, Daniel; PANDYA, Bhaumik; OZBOYA, Kerem; LUCAS, Matthew; BOURDONNEC, Bertrand Le; (259 pag.)US2019/330198; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Into a 500-mL round-bottom flask was placed 5-cyclopropyl-1,2-oxazole-3- carboxylic acid (6.12 g, 39.96 mmol, 1.00 equiv), tert-butyl (2R)-4-amino-2- methylpiperidine-1-carboxylate (8.57 g, 39.99 mmol, 1.00 equiv), dichloromethane (300 g), TEA (12.12 g, 120.00 mmol, 3.00 equiv) and HATU (22.8 g, 60.00 mmol, 1.50 equiv). The resulting solution was stirred for 15 h at room temperature. The resulting mixture was then washed with 2x100mL of Na2CO3 (1M, aq.). Then the organic phase was dried over Na2SO4 and concentrated under vacuum. The residue was purified by column chromatography (C18 gel, CH3CN/H2O = 1:1) to give 10.8 g diastereomeric tert- butyl 4-(5-cyclopropylisoxazole-3-carboxamido)-2-methylpiperidine-1-carboxylate. Then the purified product was separated by Prep-SFC with the following conditions (prep SFC 350): Column, CHIRALPAK AD-H SFC, 5x25cm,5um; mobile phase, CO2(50%), methanol(50%); Detector, uv 220nm. This was resulted in 7.48 g (54%) of tert-butyl (2R,4R)-4-(5-cyclopropyl-1,2-oxazole-3-amido)-2-methylpiperidine-1-carboxylate as light yellow oil. 1H-NMR (300 MHz, CDCl3): 6.86 (d, J = 6.9 Hz, 1H), 6.33 (s, 1H), 4.30-4.15 (m, 2H), 3.93-3.80(m, 1H), 3.22-3.07(m, 1H), 2.20-1.90 (m, 3H), 1.79-1.65(m, 2H), 1.46(s, 9H), 1.26(d, J = 6.9 Hz, 3H), 1.17-1.06(m, 2H), 1.06-0.94(m, 2H) ppm. LCMS (method A, ESI): RT=1.46 min, m/z =372.2 [M+H]+. And 2.52 g (18%) of tert- butyl (2R,4S)-4-(5-cyclopropyl-1,2-oxazole-3-amido)-2-methylpiperidine-1-carboxylate as a light yellow solid. 1H-NMR (300 MHz, CDCl3): 6.55 (d, J = 8.1 Hz, 1H), 6.33 (s, 1H), 4.63-4.39 (m, 1H), 4.39-4.15(m, 1H), 4.15-3.95(m, 1H), 3.0-2.85 (m, 1H), 2.15- 1.98(m, 2H), 1.92-1.78(m, 1H), 1.65-1.50 (m, 1H), 1.46(s, 9H), 1.42-1.26 (m, 1H), 1.23(d, J = 6.9 Hz, 3H), 1.17-1.06(m, 2H), 1.06-0.94(m, 2H) ppm. LCMS (method A, ESI): RT=1.46 min, m/z =372.2 [M+H]+.

110256-15-0, The synthetic route of 110256-15-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; EPIZYME, INC.; MITCHELL, Lorna Helen; BELL, Andrew Simon; CHESWORTH, Richard; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MILLS, James Edward John; MUNCHHOF, Michael John; (375 pag.)WO2016/40515; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a mixture of 5-cyclopropylisoxazole-3-carboxylic acid (50 mg, 0.32 mmol) in DMF (1 mL) was added HATU (120 mg, 0.32 mmol) under N2, the mixture was stirred for 30 mm, then c/s-i[5 -[3 -(trifluoromethoxy)cyclobutylj -1,3 ,4-oxadiazol-2-yl Ibicyclo [1.1.1 jpentan-3 -amine hydrochloride (8:1 to 10:1 favoring the cis- diastereomer) (89 mg, 0.27 mmol) and DIEA (140 mg, 1.1 mmol) were added to the solution at 0 C. The reaction mixture was stirred at 20 C for 12 h. The reaction mixture was quenched by addition of H20 (10 mL) at 0 C and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The cmde reaction mixture was purified employing reverse- phase HPLC. LC-MS, mlz = 425.3 [M+Hfb. ?H-NMR (400 MHz, CDC13): 7.25 (s, 1H), 6.32 (s, 1H), 4.71 (quin, J= 7.56 Hz, 1H), 3.40-3.26 (m, 1H), 2.94-2.81 (m, 2H), 2.74-2.69 (m, 2H), 2.686H), 2.15-2.03 (m, 1H), 1.19-1.08 (m, 2H), 1.03-0.94 (m, 2H).

110256-15-0, As the paragraph descriping shows that 110256-15-0 is playing an increasingly important role.

Reference£º
Patent; DENALI THERAPEUTICS INC.; CRAIG, Robert A., II; ESTRADA, Anthony A.; FENG, Jianwen A.; FOX, Brian; HALE, Christopher R. H.; LEXA, Katrina W.; OSIPOV, Maksim; REMARCHUCK, Travis; SWEENEY, Zachary K.; DE VICENTE FIDALGO, Javier; (187 pag.)WO2019/32743; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110256-15-0,5-Cyclopropylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

To a solution of 5-cyclopropylisoxazole-3-carboxylic acid (lOOmg, 0.653mmol) in DMF (2ml) was added HATU (370 mg, 0.980 mmol). The reaction stirred at room temperature for 30 minutes and then was cooled to 0C. l-Cyclopropyl-4- methylpyrrolidin-3 -amine (109 mg, 0.781 mmol) was added followed by DIPEA (252 mg, 1.960 mmol). The reaction stirred at ambient temperature for 2 hours. After completion of the reaction the reaction mixture was poured into 50 ml of water. The aqueous phase was extracted with ethyl acetate (3 x 25ml). The combined organic extracts were washed with brine, dried over sodium sulfate and concentrated under vacuum. The material was purified using column chromatography. The product was eluted at 2% MeOH in DCM. Appropriate fractions were combined and concentrated under vacuum to get 150 mg (83.79 %) of 5-cyclopropyl-N-(l-cyclopropyl-4- methylpyrrolidin-3-yl)isoxazole-3-carboxamide as a mixture of enantiomers and diastereomers. Cis and trans isomers were seperated out by chiral preparative HPLC using 0.1% TFA in hexanes/isopropanol as mobile phase to afford 35 mg of (¡À)-cis-5- cyclopropyl-N-(l-cyclopropyl-4-methylpyrrolidin-3-yl)isoxazole-3-carboxamide (Fraction- 1) and 49 mg of (¡À)-tra/?5-5-cyclopropyl-N-(l-cyclopropyl-4-methylpyrrolidin- 3 -yl)isoxazole-3 -carboxamide (Fraction-2) . [0196] (¡À)-cz5-5-cyclopropyl-N-(l-cyclopropyl-4-methylpyrrolidin-3-yl)isoxazole-3- carboxamide: 1H NMR (400 MHz, MeOD): delta 6.41 (s, 1H), 4.33 (bs, 1H), 3.94-3.66 (m, 3H), 3.15-3.00 (m, 2H), 2.56-2.53 (m, 1H), 2.22-2.15 (m, 1H), 1.37-1.33 (d, J = 18.4 Hz, 3H), 1.23 (d, J = 6.8 Hz, 2H), 1.00-0.99 (m, 5H); LCMS: m/z = 277.23 [M+H]+. [0197] (¡À)-tra/?5-5-cyclopropyl-N-(l-cyclopropyl-4-methylpyrrolidin-3-yl)isoxazole-3- carboxamide: 1H NMR (400 MHz, MeOD): delta 6.42 (s, 1H), 4.15 (bs, 1H), 3.77-3.66 (m, 3H), 3.52-3.37 (m, 2H), 3.04 (bs, 2H), 2.62 (bS, 1H), 2.22-2.26 (m, 1H), 1.19-1.12 (m, 2H), 1.09 (d, J = 7.2 Hz, 3H), 1.01-0.98 (m, 5H), 0.97-0.90 (m, 2H); LCMS: m/z = 276.18 [M+H]+.

110256-15-0, As the paragraph descriping shows that 110256-15-0 is playing an increasingly important role.

Reference£º
Patent; EPIZYME, INC.; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MITCHELL, Lorna Helen; MUNCHHOF, Michael John; HARVEY, Darren Martin; (151 pag.)WO2016/40504; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (1.0 g, 6.5 mmol) in DMF (3 mL) was added HATU (3.72 g, 9.8 mmol) and diisopropylethylamine (3.5 ml, 19.6 mmol). The solution was stirred for 10 min at 0 C. tert-Butyl 4-(l- aminoethyl)piperidine-l-carboxylate (1.45 g, 6.5 mmol) was added and the reaction stirred at RT for 2 h. The progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction was quenched with water and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous Na2S04 and concentrated under reduced pressure to obtain a crude residue which was purified by column chromatography to afford compound tert-butyl 4-(l-(5- cyclopropylisoxazole-3-carboxamido)ethyl)piperidine-l-carboxylate (2.1 g, 84%). 1H NMR (400 MHz, OMSO-d6) delta 8.44 (d, J = 8.9 Hz, 1H), 6.46 (s, 1H), 3.98-3.90 (m, 2H), 3.79 (p, J = 7.3 Hz, 1H), 2.53-2.47 (m, 2H), 2.19-2.16 (m, 1H), 1.6-1.58 (m, 3H), 1.38 (s, 9H), 1.18-0.86 (m, 9H); LCMS: m/z = 386.25 (M+H)+.

110256-15-0, As the paragraph descriping shows that 110256-15-0 is playing an increasingly important role.

Reference£º
Patent; EPIZYME, INC.; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MILLS, James Edward John; MITCHELL, Lorna Helen; MUNCHHOF, Michael John; HARVEY, Darren Martin; (208 pag.)WO2016/40498; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem